Table 6.
Feature | BCS | Mastectomy | p Value | Relative risk* (95% CI) |
---|---|---|---|---|
Age (y), mean (SD) | 66.7 (10.05) | 66.6 (10.1) | 0.97 | |
Biomarker | ||||
ER+/PR+ | 34 | 35 | 0.82 | |
ER+/PR− | 14 | 13 | ||
Pre-AI cT stage | ||||
cT2 | 36 | 16 | ||
cT3/4 | 12 | 32 | <0.0001 | 2.4 (1.5–3.7) |
Clinical N stage | ||||
cN0 | 31 | 29 | 0.67 | |
cN1/2 | 17 | 19 | ||
Histologic subtype | ||||
Ductal | 39 | 33 | ||
Lobular† | 9 | 15 | 0.16 | |
Pre-AI surgical status | ||||
Marginal BCS | 30 | 16 | ||
Ineligible BCS‡ | 15 | 24 | 0.0042 | 1.84 (1.18–2.88) |
Inoperable | 3 | 8 | ||
Clinical response | ||||
PR + CR | 35 | 26 | ||
SD + PD | 11 | 19 | 0.0632 | 1.49 (1.0–2.2) |
Post-AI cT stage | ||||
cT0/1 | 24 | 9 | ||
cT2/3/4 | 24 | 39 | 0.0013 | 2.27 (1.26–4.1) |
Pathologic T stage | ||||
p < T2 | 47 | 32 | ||
pT3,4 | 1 | 16 | <0.0001 | 2.32 (1.73–3.11) |
Pathologic N stage | ||||
pN0 | 28 | 11 | ||
pN1–3 | 20 | 37 | 0.0004 | 2.3 (1.35–3.9) |
Relative risks and 95% CI of having a mastectomy were calculated with a feature’s lower level as reference.
Includes ductal with lobular features.
cT and cN indicates clinical T and N stage.
AI, aromatase inhibitor; BCS, breast-conserving surgery; CR, complete response; ER, estrogen receptor; PD, progressive disease; PR, progesterone receptor; SD, stable disease.